AnaptysBio Inc (ANAB)

Currency in USD
47.98
+0.92(+1.96%)
Real-time Data·
High dividend Yield
ANAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
46.9049.71
52 wk Range
33.1073.30
Key Statistics
Prev. Close
47.06
Open
48.41
Day's Range
46.9-49.71
52 wk Range
33.1-73.3
Volume
154.32K
Average Volume (3m)
489.69K
1-Year Change
28.722%
Book Value / Share
0.70
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
87.25
Upside
+81.85%
Members' Sentiments
Bearish
Bullish
ProTips
Pays a significant dividend to shareholders

AnaptysBio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 87.25
(+81.85% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy60.00+25.97%70.00MaintainSep 30, 2026
H.C. Wainwright
Buy95.00+99.45%-MaintainSep 22, 2026
Wolfe Research
Buy78.00+63.76%-MaintainAug 31, 2026
TD Cowen
Buy70.00+46.97%75.00MaintainAug 25, 2026
H.C. Wainwright
Buy95.00+99.45%-New CoverageJun 10, 2026

Earnings

Latest Release
Sep 21, 2026
EPS / Forecast
5.11 / 5.11
Revenue / Forecast
27.49M / 27.49M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.18
Dividend Yield
47.83%
Industry Median 0.66%
Annualized payout
22.51
Paid unevenly
5-Years Growth
-
Growth Streak

ANAB Income Statement

Compare ANAB to Peers and Sector

Metrics to compare
ANAB
Peers
Sector
Relationship
P/E Ratio
4.7x−0.9x−0.2x
PEG Ratio
0.01−0.050.00
Price/Book
68.2x2.3x2.6x
Price / LTM Sales
23.6x5.8x2.7x
Upside (Analyst Target)
84.3%178.9%69.6%
Fair Value Upside
Unlock23.9%11.7%Unlock

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.60M25.44%357.84M
Other Institutional Investors
25.31M74.56%1.19B
Public Companies & Retail Investors
0.000.00%0.00
Total
32.92M100.00%1.55B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
EcoR1 Capital, LLC26.36%7,880,094370,837
BlackRock, Inc.6.17%1,844,04986,781

People Also Watch

19.355
WT
-3.23%
8.71
CGEM
-3.33%
22.85
TNGX
+4.39%
94.71
KNSA
-0.36%
10.69
FDMT
+2.20%

FAQ

What Is the AnaptysBio (ANAB) Stock Price Today?

The AnaptysBio stock price today is 47.98 USD.

What Stock Exchange Does AnaptysBio Trade On?

AnaptysBio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for AnaptysBio?

The stock symbol for AnaptysBio is "ANAB."

Does AnaptysBio Pay Dividends? What’s The Current Dividend Yield?

The AnaptysBio dividend yield is 47.8%%.

What Is the AnaptysBio Market Cap?

As of today, AnaptysBio market cap is 1.42B USD.

What Is AnaptysBio's Earnings Per Share (TTM)?

The AnaptysBio EPS (TTM) is 10.18.

From a Technical Analysis Perspective, Is ANAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has AnaptysBio Stock Split?

AnaptysBio has split 0 times.

How Many Employees Does AnaptysBio Have?

AnaptysBio has 104 employees.

What is the current trading status of AnaptysBio (ANAB)?

As of Nov 19, 2026, AnaptysBio (ANAB) is trading at a price of 47.98 USD, with a previous close of 47.06 USD. The stock has fluctuated within a day range of 46.90 USD to 49.71 USD, while its 52-week range spans from 33.10 USD to 73.30 USD.

What Is AnaptysBio (ANAB) Price Target According to Analysts?

The average 12-month price target for AnaptysBio is 87.25 USD, with a high estimate of 140 USD and a low estimate of 60 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +81.85% Upside potential.

What Is the ANAB Premarket Price?

ANAB's last pre-market stock price is 48.42 USD. The pre-market share volume is 5,930.00, and the stock has decreased by 1.36, or 2.89%.

What Is the ANAB After Hours Price?

ANAB's last after hours stock price is 47.74 USD, the stock has decreased by 0.68, or 1.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.